Deals this week: Carma Therapeutics, Vectorite Biomedica, Loxo Oncology


Cellular immunotherapies developer Carma Therapeutics has completed a venture financing round co-led by AbbVie Biotech Ventures and HealthCap in order to raise funds required to advance the development of its adoptive cellular immunotherapy named CARMA-0508.

The round also saw the participation of Grazia Equity and IP Group.

Taiwanese biotechnology company Vectorite Biomedica plans for a rights offering of shares of its common stock to raise TWD41.63m ($1.37m) in gross proceeds.

The company will issue 2.5 million new shares priced at TWD18.5 ($0.6) each as part of the offering.

The company’s employees will be issued 10% of the shares, the equivalent of 250,000 shares, while the remaining will be issued to the existing shareholders.

"Taiwanese biotechnology company Vectorite Biomedica plans for a rights offering of shares of its common stock to raise TWD41.63m ($1.37m) in gross proceeds."

The proceeds from the offering will be used for working capital purposes.

US-based biopharmaceutical company Loxo Oncology has announced an underwritten public offering of shares of its common stock to raise funds needed for early commercialisation of larotrectinib, research and development activities, and general corporate purposes.

Underwriters for the offering will be granted an option to purchase additional shares within 30 days.

Aequus Pharmaceuticals and Santen Pharmaceutical’s subsidiary Santen has signed an agreement for the commercialisation of an undisclosed ophthalmology therapeutic product in Canada that currently awaits Health Canada’s marketing approval.

Aequus Pharmaceuticals is a specialist Canadian pharmaceutical company, while Santen is an ophthalmology company based in the US.